Recruiting Head and Neck Cancer Studies in New Haven
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)...
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and ...
A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202
The primary purpose of the study is to evaluate the antitumor activity and safety of novel immunotherapy combinations compared with dostarlimab in participants with Programmed death ligand 1 (PD-L1) p...
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
An open-label, controlled, multi-site, interventional, 2-arm, Phase II/III trial of BNT113 in combination with pembrolizumab vs pembrolizumab monotherapy as first line treatment in patients with unres...
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in...
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
The purpose of this study is to compare any good or bad effects of using pembrolizumab (an experimental drug) and radiation therapy (RT), compared to using cisplatin chemotherapy and radiation therapy...
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
This is a Phase 2 study designed to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with cemiplimab. The study will enroll patients with three distinct separ...
About Head and Neck Cancer Clinical Trials in New Haven
Head and neck cancers develop in the mouth, throat, larynx, sinuses, or salivary glands. HPV-related oropharyngeal cancers have been increasing in prevalence. Treatment includes surgery, radiation, chemotherapy, and immunotherapy.
There are currently 7 head and neck cancer clinical trials recruiting participants in New Haven, CONNECTICUT. These studies are seeking a combined 2,432 participants. Research is being sponsored by GlaxoSmithKline, AVEO Pharmaceuticals, Inc., BioNTech SE and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Head and Neck Cancer Clinical Trials in New Haven — FAQ
Are there head and neck cancer clinical trials in New Haven?
Yes, there are 7 head and neck cancer clinical trials currently recruiting in New Haven, CONNECTICUT. Browse the studies on this page to find one that fits.
How do I join a clinical trial in New Haven?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Haven research site will contact you about next steps.
Are clinical trials in New Haven free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Haven studies also compensate for your time and travel.
What head and neck cancer treatments are being tested?
The 7 active trials in New Haven are testing new therapies including novel drugs, biologics, and treatment approaches for head and neck cancer.
Data updated March 2, 2026 from ClinicalTrials.gov